Hemab Therapeutics, a late stage clinical biotechnology company developing novel prophylactic therapeutics for serious, underserved coagulation disorders, today announced that the U.S. Food and Drug ...

Sutacimig is an investigational bispecific antibody designed to bind to endogenous factor VIIa and localize it to activated platelets, thereby promoting thrombin and fibrin formation.

A breakthrough study features a biomedical engineering innovation with the potential to transform trauma care and surgical practices. A scientific research team has developed platelet-like particles ...

An expert explains the unique dosing considerations for emicizumab compared to factor VIII in hemophilia A, covering prophylaxis and breakthrough bleeding scenarios. This is a video synopsis/summary ...